Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Oct;18(4):377-379.
doi: 10.1007/s10689-019-00142-8.

Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?

D Gareth Evans  1   2   3   4 , Sacha J Howell  5   6   7 , Anthony Howell  5   6   7
Affiliations
Editorial

Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?

D Gareth Evans et al. Fam Cancer. 2019 Oct.
No abstract available

PubMed Disclaimer

Comment on

  • Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.
    Heemskerk-Gerritsen BAM, Jager A, Koppert LB, Obdeijn AI, Collée M, Meijers-Heijboer HEJ, Jenner DJ, Oldenburg HSA, van Engelen K, de Vries J, van Asperen CJ, Devilee P, Blok MJ, Kets CM, Ausems MGEM, Seynaeve C, Rookus MA, Hooning MJ. Heemskerk-Gerritsen BAM, et al. Breast Cancer Res Treat. 2019 Oct;177(3):723-733. doi: 10.1007/s10549-019-05345-2. Epub 2019 Jul 13. Breast Cancer Res Treat. 2019. PMID: 31302855 Free PMC article.

References

    1. Heemskerk-Gerritsen Bernadette A. M., Jager Agnes, Koppert Linetta B., Obdeijn A. Inge-Marie, Collée Margriet, Meijers-Heijboer Hanne E. J., Jenner Denise J., Oldenburg Hester S. A., van Engelen Klaartje, de Vries Jakob, van Asperen Christi J., Devilee Peter, Blok Marinus J., Kets C. Marleen, Ausems Margreet G. E. M., Seynaeve Caroline, Rookus Matti A., Hooning Maartje J. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. 2019;177(3):723–733. doi: 10.1007/s10549-019-05345-2. - DOI - PMC - PubMed
    1. Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction. strategies for BRCA1/2 mutation carriers. J Clin Oncol. 2010;28(2):222–231. doi: 10.1200/JCO.2009.22.7991. - DOI - PMC - PubMed
    1. Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, Mills MA, Plevritis SK. Online tool to guide decisions for BRCA1/2 mutation carriers. J Clin Oncol. 2012;30(5):497–506. doi: 10.1200/JCO.2011.38.6060. - DOI - PMC - PubMed
    1. Evans DG, Harkness EF, Howell A, Wilson M, Hurley E, Holmen MM, Tharmaratnam KU, Hagen AI, Lim Y, Maxwell AJ, Moller P. Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all-cause mortality. Hered Cancer Clin Pract. 2016;14(1):8. doi: 10.1186/s13053-016-0048-3. - DOI - PMC - PubMed
    1. Saadatmand S, Obdeijn IM, Rutgers EJ, Oosterwijk JC, Tollenaar RA, Woldringh GH, et al. Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC) Int J Cancer. 2015;137(7):1729–1738. doi: 10.1002/ijc.29534. - DOI - PubMed